Pre-made Rosopatamab Tetraxetan benchmark antibody (Whole mAb ADC, anti-FOLH1/GCPII therapeutic antibody, Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Rosopatamab Tetraxetan benchmark antibody (Whole mAb ADC, anti-FOLH1/GCPII therapeutic antibody, Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-979
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Rosopatamab Tetraxetan Biosimilar, Whole Mab Adc, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody Drug Conjugate |
---|---|
INN Name | rosopatamab tetraxetan |
Target | FOLH1 |
Format | Whole mAb ADC |
Derivation | Chimeric |
Species Reactivity | Human |
CH1 Isotype | IgG1 – kappa |
VD LC | IgG1 – kappa |
Highest_Clin_Trial (Jan '20) | NA |
Est. Status | NA |
100% SI Structure | NA |
99% SI Structure | NA |
95-98% SI Structure | NA |
Year Proposed | NA |
Year Recommended | NA |
Companies | Weill?Cornell Medical (New York NY USA) |
Conditions Approved | NA |
Conditions Active | NA |
Conditions Discontinued | NA |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | FOLH1 |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide